文献速递心律失常

筛查未诊断房颤对卒中预防的影响:GUARD-AF随机对照试验

Effect of Screening for Undiagnosed Atrial Fibrillation on Stroke Prevention.
PubMed 文献 · J Am Coll Cardiol · 2024-09-01

GUARD-AF试验在≥70岁初级保健人群中比较14天连续心电监测筛查房颤与常规护理,筛查组卒中住院风险0.7% vs 常规组0.6%(HR 1.10,95%CI 0.69-1.75),出血风险无差异,筛查未显著降低卒中住院。

要点

  • ≥70岁人群14天心电贴片筛查未显著降低卒中住院风险(HR 1.10,95%CI 0.69-1.75)。
  • 筛查组房颤诊断率5% vs 常规组3.3%,口服抗凝启动率4.2% vs 2.8%。
  • 筛查组与常规组出血风险相似(HR 0.87,95%CI 0.60-1.26)。

核心结论

  • 在≥70岁初级保健人群中,14天连续心电监测筛查房颤未显著减少卒中住院,但事件率低且试验未达到计划样本量。

研究设计与样本

  • GUARD-AF为前瞻性平行组随机对照试验,在美国149个初级保健站点纳入≥70岁人群,1:1随机至筛查或常规护理,意向性治疗分析共11905例,中位随访15.3个月。

主要发现

  • 筛查组卒中住院风险0.7% vs 常规组0.6%(HR 1.10,95%CI 0.69-1.75)。
  • 筛查组出血风险1.0% vs 常规组1.1%(HR 0.87,95%CI 0.60-1.26)。
  • 筛查组房颤诊断率5% vs 常规组3.3%,随机化后口服抗凝启动率4.2% vs 2.8%。

临床怎么用

  • 在≥70岁初级保健人群中,14天心电监测筛查房颤虽提高诊断率和抗凝启动率,但未证实降低卒中住院,支持个体化决策而非普遍筛查。

局限性

  • COVID-19大流行导致入组提前终止,未达到计划样本量。
  • 事件率低,可能影响统计效能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atrial fibrillation (AF) often remains undiagnosed, and it independently raises the risk of ischemic stroke, which is largely reversible by oral anticoagulation. Although randomized trials using longer term screening approaches increase identification of AF, no studies have established that AF screening lowers stroke rates. OBJECTIVES: To address this knowledge gap, the GUARD-AF (Reducing Stroke by Screening for Undiagnosed Atrial Fibrillation in Elderly Individuals) trial screened participants in primary care practices using a 14-day continuous electrocardiographic monitor to determine whether screening for AF coupled with physician/patient decision-making to use oral anticoagulation reduces stroke and provides a net clinical benefit compared with usual care. METHODS: GUARD-AF was a prospective, parallel-group, randomized controlled trial designed to test whether screening for AF in people aged ≥70 years using a 14-day single-lead continuous electrocardiographic patch monitor could identify patients with undiagnosed AF and reduce stroke. Participants were randomized 1:1 to screening or usual care. The primary efficacy and safety outcomes were hospitalization due to all-cause stroke and bleeding, respectively. Analyses used the intention-to-treat population. RESULTS: Enrollment began on December 17, 2019, and involved 149 primary care sites across the United States. The COVID-19 pandemic led to premature termination of enrollment, with 11,905 participants in the intention-to-treat population. Median follow-up was 15.3 months (Q1-Q3: 13.8-17.6 months). Median age was 75 years (Q1-Q3: 72-79 years), and 56.6% were female. The risk of stroke in the screening group was 0.7% vs 0.6% in the usual care group (HR: 1.10; 95% CI: 0.69-1.75). The risk of bleeding was 1.0% in the screening group vs 1.1% in the usual care group (HR: 0.87; 95% CI: 0.60-1.26). Diagnosis of AF was 5% in the screening group and 3.3% in the usual care group, and initiation of oral anticoagulation after randomization was 4.2% and 2.8%, respectively. CONCLUSIONS: In this trial, there was no evidence that screening for AF using a 14-day continuous electrocardiographic monitor in people ≥70 years of age seen in primary care practice reduces stroke hospitalizations. Event rates were low, however, and the trial did not enroll the planned sample size.(Reducing Stroke by Screening for Undiagnosed Atrial Fibrillation in Elderly Individuals [GUARD-AF]; NCT04126486).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Lopes, Atlas, Go, et al. Effect of Screening for Undiagnosed Atrial Fibrillation on Stroke Prevention. J Am Coll Cardiol. 2024. PMID: 39230544. doi:10.1016/j.jacc.2024.08.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。